Belapectin (GR-MD-02)
MASH Cirrhosis with Portal Hypertension
Key Facts
About Galectin Therapeutics
Galectin Therapeutics is pioneering therapies targeting galectin-3, a protein implicated in inflammatory, fibrotic, and malignant diseases. Its primary mission is to address the unmet medical need in MASH cirrhosis, the fastest-growing cause of liver transplantation, through its lead drug candidate belapectin. The company is currently advancing its NAVIGATE Phase 3 clinical trial and recently strengthened its financial position with a $10 million credit facility. Galectin's platform also holds potential in oncology by modulating the tumor microenvironment to enhance immunotherapy responses.
View full company profileAbout Galectin Therapeutics
Galectin Therapeutics is pioneering therapies targeting galectin-3, a protein implicated in inflammatory, fibrotic, and malignant diseases. Its primary mission is to address the unmet medical need in MASH cirrhosis, the fastest-growing cause of liver transplantation, through its lead drug candidate belapectin. The company is currently advancing its NAVIGATE Phase 3 clinical trial and recently strengthened its financial position with a $10 million credit facility. Galectin's platform also holds potential in oncology by modulating the tumor microenvironment to enhance immunotherapy responses.
View full company profileAbout Galectin Therapeutics
Galectin Therapeutics is pioneering therapies targeting galectin-3, a protein implicated in inflammatory, fibrotic, and malignant diseases. Its primary mission is to address the unmet medical need in MASH cirrhosis, the fastest-growing cause of liver transplantation, through its lead drug candidate belapectin. The company is currently advancing its NAVIGATE Phase 3 clinical trial and recently strengthened its financial position with a $10 million credit facility. Galectin's platform also holds potential in oncology by modulating the tumor microenvironment to enhance immunotherapy responses.
View full company profile